Immunomedics' CEA assay data to be re-analysed
This article was originally published in Clinica
Although Immunomedics had hoped for a recommendation for approval for its colorectal imaging agent, CEA-Scan (arcitumomab) assay, on October 17th, the company appreciates that the US FDA oncologic drugs advisory panel "was not necessarily the correct advisory group to evaluate a diagnostic imaging agent". The panel requested that review of the agent be reassigned to a medical imaging devices advisory committee (see Clinica No 677, p 15).
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.